Drug-induced liver injury (DILI) is one of leading causes of attrition during both early and late stages of drug development and postmarketing. DILI is generally classiˆed into the intrinsic and idiosyncratic types. Intrinsic DILI is dose dependent and predictable as exempliˆed by acetaminophen toxicity. However, the occurrence of idiosyncratic DILI with very low incidence and severe liver damage is di‹cult to predict because of the complex nature of DILI and poor understanding of its mechanism. In this review, we summarize current knowledge and our accumulated experimentalˆndings on the pathogenic mechanisms of DILI focusing on the reactive metabolites of drugs formed by drugmetabolizing enzymes and immune-and in‰ammation-related responses. Considering drug metabolism and pharmacokinetics, we have established nonclinical animal models of DILI for 10 types of clinical drug known to cause idiosyncratic DILI in humans. Using animal models, it has been shown that the formation of reactive metabolites and both innate and adaptive immunity are involved in the pathogenesis of drug hepatotoxicity. Based on information on biomarkers obtained from animal models, we developed a cell-based system that predicts the potential DILI risks of drugs. The results of these studies increased our understanding of the mechanisms of DILI and help to predict and prevent idiosyncratic DILI caused by drug candidates.
については，BALB/c マウスに発症させた肝障害に The value was deˆned as an integrated score of the relative expression levels of NALP3 mRNA in K562 cells, and RAGE, S100A8, S100A9, and IL-1b mRNA in HL-60 cells incubated with and without HLMs. The expression level of hepatic mRNA was normalized to that of GAPDH mRNA. WDN, withdrawn; BBW, black box warning; WNG, warning. 
